Targeting metabolic changes in cancer: Novel therapeutic approaches

Annual Review of Medicine

Volumn 65, Issue , 2014, Pages 157-170

  Bobrovnikova Marjon, Ekaterina ^a   Hurov, Jonathan B ^a  

^a AGIOS PHARMACEUTICALS   (United States)

Author keywords

Antimetabolites; Glutamine; Isocitrate dehydrogenase; Nucleotide synthesis

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; ENOLASE; GLUTAMINASE; GLUTAMINE; ISOCITRATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NUCLEOTIDE; SMALL MOLECULE TRANSPORT AGENT;

ARTICLE; BIOSYNTHESIS; CANCER CELL; CANCER METABOLISM; CANCER THERAPY; CARCINOGENESIS; CELL SELECTION; DRUG TARGETING; FATTY ACID OXIDATION; HUMAN; METABOLISM; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; DNA-BINDING PROTEINS; FATTY ACIDS; GLUTAMINE; HUMANS; ISOCITRATE DEHYDROGENASE; METHOTREXATE; NAD; NEOPLASMS; PHOSPHOPYRUVATE HYDRATASE; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84901487313     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-092012-112344     Document Type: Article

References (92)

1. Lunt SY, Vander Heiden MG. 2011. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27:441-64
2. Yuneva MO, Fan TW, Allen TD, et al. 2012. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 15:157-70
3. WarburgO, Wind F, Negelein E. 1927. Themetabolism of tumors in the body. J. Gen. Physiol. 8:519-30
4. Farber S, Diamond LK. 1948. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N. Engl. J. Med. 238:787-93
5. Moran RG, Mulkins M, Heidelberger C. 1979. Role of thymidylate synthetase activity in development of methotrexate cytotoxicity. Proc. Natl. Acad. Sci. USA 76:5924-28
6. Hazarika M, White RM, Johnson JR, et al. 2004. FDA drug approval summaries: pemetrexed (Alimta). Oncologist 9:482-88 (Pubitemid 39332311)
7. Elion GB. 1989. Nobel Lecture. The purine path to chemotherapy. Biosci. Rep. 9:509-29
8. Elion GB, Hitchings GH. 1950. Antagonist of nucleic acid derivatives. III. The specificity of the purine requirement of Lactobacillus casei. J. Biol. Chem. 185:651-55
9. Hitchings GH. 1992. Antagonists of nucleic acid derivatives as medicinal agents. Annu. Rev. Pharmacol. Toxicol. 32:1-6
10. Longley DB, HarkinDP, Johnston PG. 2003. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3:330-38
11. Heidelberger C, Chaudhuri NK, Danneberg P, et al. 1957. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179:663-66
12. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. InternationalMulticentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345:939-44
13. Goldin A, Venditti JM, Kline I, et al. 1966. Eradication of leukaemic cells (L1210) by methotrexate and methotrexate plus citrovorum factor. Nature 212:1548-50
14. Wright JE, Dreyfuss A, el-Magharbel I, et al. 1989. Selective expansion of 5, 10- methylenetetrahydrofolate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo. Cancer Res. 49:2592-96
15. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J. Clin. Oncol. 10:896-903
16. LeeHY, AhnHK, Jeong JY, et al. 2013. Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer. Lung Cancer 79:40-45
17. Scagliotti G, Hanna N, Fossella F, et al. 2009. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14:253-63
18. Shaw AT, Varghese AM, Solomon BJ, et al. 2013. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann. Oncol. 24:59-66
19. Lubin M, Lubin A. 2009. Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy. PLoS One 4:e5735
20. Hori H, Tran P, Carrera CJ, et al. 1996. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells. Cancer Res. 56:5653-58 (Pubitemid 26422168)
21. Tang B, Testa JR, Kruger WD. 2012. Increasing the therapeutic index of 5-fluorouracil and 6- thioguanine by targeting loss of MTAP in tumor cells. Cancer Biol. Ther. 13:1082-90
22. KindlerHL, BurrisHA 3rd, Sandler AB, et al. 2009. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Invest. New Drugs 27:75-81
23. Ruefli-Brasse A, Sakamoto D, Orf J, et al. 2011. Methylthioadenosine (MTA) rescues methylthioadenosine phosphorylase (MTAP)-deficient tumors from purine synthesis inhibition in vivo via nonautonomous adenine supply. J. Cancer Ther. 2:523-34
24. Ben-Sahra I, Howell JJ, Asara JM, et al. 2013. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 339:1323-28
25. Robitaille AM, Christen S, Shimobayashi M, et al. 2013. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339:1320-23
26. Muller FL, Colla S, Aquilanti E, et al. 2012. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488:337-42
27. Jung DW, Kim WH, Park SH, et al. 2013. A unique small molecule inhibitor of enolase clarifies its role in fundamental biological processes. ACS Chem. Biol. 8:1271-82
28. Yan H, Parsons DW, Jin G, et al. 2009. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360:765-73
29. Mardis ER, Ding L, Dooling DJ, et al. 2009. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361:1058-66
30. Dang L, White DW, Gross S, et al. 2009. Cancer-associated IDH1 mutations produce 2- hydroxyglutarate. Nature 462:739-44
31. Kaelin WG Jr. 2011. Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb. Symp. Quant. Biol. 76:335-45
32. Xu W, Yang H, Liu Y, et al. 2011. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17-30
33. Chowdhury R, Yeoh KK, Tian YM, et al. 2011. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 12:463-69
34. Figueroa ME, Abdel-Wahab O, Lu C, et al. 2010. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-67
35. Grassian AR, Lin F, Barrett R, et al. 2012. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). J. Biol. Chem. 287:42180-94
36. Ward PS, Patel J, Wise DR, et al. 2010. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225-34
37. Rohle D, Popovici-Muller J, Palaskas N, et al. 2013. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340:626-30
38. Wang F, Travins J, Delabarre B, et al. 2013. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340:622-26
39. Caro P, Kishan AU, Norberg E, et al. 2012. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell 22:547-60
40. Monti S, SavageKJ, Kutok JL, et al. 2005. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105:1851-61 (Pubitemid 40731764)
41. Carracedo A, Cantley LC, Pandolfi PP. 2013. Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer 13:227-32
42. Schafer ZT, Grassian AR, Song L, et al. 2009. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461:109-13
43. Samudio I, Harmancey R, Fiegl M, et al. 2010. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Invest. 120:142-56
44. Kantor PF, Lucien A, Kozak R, et al. 2000. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3- ketoacyl coenzyme A thiolase. Circ. Res. 86:580-88
45. Nash DT, Nash SD. 2008. Ranolazine for chronic stable angina. Lancet 372:1335-41
46. Killalea SM, Krum H. 2001. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am. J. Cardiovasc. Drugs 1:193-204
47. Chiarugi A, Dolle C, Felici R, et al. 2012. The NAD metabolome-a key determinant of cancer cell biology. Nat. Rev. Cancer 12:741-52
48. Bi TQ, Che XM, Liao XH, et al. 2011. Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil. Oncol. Rep. 26:1251-57
49. Shackelford RE, Bui MM, Coppola D, et al. 2010. Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers. Int. J. Clin. Exp. Pathol. 3:522-27
50. Wang B, HasanMK, Alvarado E, et al. 2011. NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene 30:907-21
51. Cea M, Zoppoli G, Bruzzone S, et al. 2009. APO866 activity in hematologic malignancies: a preclinical in vitro study. Blood 113:6035-37; author reply 6037-38
52. Fleischer TC, Murphy BR, Flick JS, et al. 2010. Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound. Chem. Biol. 17:659-64
53. Nahimana A, Attinger A, Aubry D, et al. 2009. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 113:3276-86
54. Tan B, Young DA, Lu ZH, et al. 2013. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications. J. Biol. Chem. 288:3500-11
55. Watson M, Roulston A, Belec L, et al. 2009. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1- deficient tumors. Mol. Cell. Biol. 29:5872-88
56. Olesen UH, Thougaard AV, Jensen PB, et al. 2010. A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol. Cancer Ther. 9:1609-17
57. Holen K, Saltz LB, Hollywood E, et al. 2008. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest. New Drugs 26:45-51
58. vonHeideman A, Berglund A, Larsson R, et al. 2010. Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother. Pharmacol. 65:1165-72
59. Goellner EM, Grimme B, Brown AR, et al. 2011. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair. Cancer Res. 71:2308-17
60. Bajrami I, Kigozi A, Van Weverwijk A, et al. 2012. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. EMBO Mol. Med. 4:1087-96
61. Eagle H, Oyama VI, Levy M, et al. 1956. The growth response of mammalian cells in tissue culture to L-glutamine and L-glutamic acid. J. Biol. Chem. 218:607-16
62. Soeters PB, Grecu I. 2012. Have we enough glutamine and how does it work? A clinician's view. Ann. Nutr. Metab. 60:17-26
63. DeBerardinis RJ, Cheng T. 2009. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29:313-24
64. Reitzer LJ, Wice BM, Kennell D. 1979. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J. Biol. Chem. 254:2669-76
65. Dang CV, Hamaker M, Sun P, et al. 2011. Therapeutic targeting of cancer cell metabolism. J. Mol. Med. (Berl.) 89:205-12
66. Ahluwalia GS, Grem JL, Hao Z, et al. 1990. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol. Ther. 46:243-71
67. Livingston RB, Venditti JM, Cooney DA, et al. 1970. Glutamine antagonists in chemotherapy. Adv. Pharmacol. Chemother. 8:57-120
68. Magill GB, Myers WP, Reilly HC, et al. 1957. Pharmacological and initial therapeutic observations on 6-diazo-5-oxo-1-norleucine (DON) in human neoplastic disease. Cancer 10:1138-50
69. Aledo JC, Gomez-Fabre PM, Olalla L, et al. 2000. Identification of two human glutaminase loci and tissue-specific expression of the two related genes. Mamm. Genome 11:1107-10
70. Elgadi KM, MeguidRA, Qian M, et al. 1999. Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol. Genomics 1:51-62 (Pubitemid 129622451)
71. Robinson MM, McBryant SJ, Tsukamoto T, et al. 2007. Novel mechanism of inhibition of rat kidneytype glutaminase by bis-2-(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem. J. 406:407-14
72. DeLaBarre B, Gross S, Fang C, et al. 2011. Full-length human glutaminase in complex with an allosteric inhibitor. Biochemistry 50:10764-70
73. Seltzer MJ, Bennett BD, Joshi AD, et al. 2010. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 70:8981-87
74. Dang CV. 2011. Therapeutic targeting of Myc-reprogrammed cancer cellmetabolism. Cold Spring Harb. Symp. Quant. Biol. 76:369-74
75. Wang J-B, Erickson JW, Fuji R, et al. 2010. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18:207-19
76. Gameiro PA, Yang J, Metelo AM, et al. 2013. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab. 17:372-85
77. Mullen AR, Wheaton WW, Jin ES, et al. 2011. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481:385-88
78. Simpson NE, Tryndyak VP, Beland FA, et al. 2011. An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression. Breast Cancer Res. Treat. 133:959-68
79. Simpson NE, Tryndyak VP, Pogribna M, et al. 2012. Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype. Epigenetics 7:1413-20
80. Currie CJ, Poole CD, Gale EA. 2009. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-77
81. Emami Riedmaier A, Fisel P, Nies AT, et al. 2013. Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol. Sci. 34:126-35
82. Ward RA, Brassington C, Breeze AL, et al. 2012. Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation. J. Med. Chem. 55:3285-306
83. ManerbaM, Vettraino M, Fiume L, et al. 2012. Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase. ChemMedChem 7:311-17
84. Le Floch R, Chiche J, Marchiq I, et al. 2011. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc. Natl. Acad. Sci. USA 108:16663-68
85. Avramis VI. 2012. Asparaginases: biochemical pharmacology and modes of drug resistance. Anticancer Res. 32:2423-37
86. Asselin BL. 2011. L-Asparaginase for treatment of childhood acute lymphoblastic leukemia: What have we learned? Pediatr. Blood Cancer 57:357-58
87. Miller HK, Salser JS, Balis ME. 1969. Amino acid levels following L-asparagine amidohydrolase (EC.3.5.1.1) therapy. Cancer Res. 29:183-87
88. Roberts J, Schmid FA, Old LJ, et al. 1976. A comparative study of the antitumor effectiveness of E. coli and Erwinia asparaginases. Cancer Biochem. Biophys. 1:175-78
89. Covini D, Tardito S, Bussolati O, et al. 2012. Expanding targets for a metabolic therapy of cancer: L-asparaginase. Recent Pat. Anticancer Drug Discov. 7:4-13
90. Avramis VI. 2011. Asparaginases: a successful class of drugs against leukemias and lymphomas. J. Pediatr. Hematol. Oncol. 33:573-79
91. Roberts J. 1976. Purification and properties of a highly potent antitumor glutaminase-asparaginase from Pseudomonas 7Z. J. Biol. Chem. 251:2119-23
92. Mueller C, Al-Batran S, Jaeger E, et al. 2008. A phase IIa study of PEGylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-L-norleucine (DON)in patientswith advanced refractory solid tumors. J. Clin.Oncol. 26:2533